Nanotherapeutic macrophage-based immunotherapy for peritoneal carcinomatosis of lung cancer

Nanoscale ◽  
2022 ◽  
Author(s):  
Yonghui Wang ◽  
Binfan Chen ◽  
Zhidi He ◽  
Bin Tu ◽  
Pengfei Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Peritoneal Carcinomatosis ◽  
High Mortality ◽  
Distant Metastasis ◽  
Cancer Mortality ◽  
Poor Prognosis ◽  
Abdominal Metastasis ◽  
The World

Lung cancer is the top cause of cancer mortality in the world. Distant metastasis leads to high mortality. Abdominal metastasis of lung cancer is characterized by a very poor prognosis...

Trends in lung cancer mortality between 2001 and 2017: An observational study in USA and EU.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19277-e19277
Author(s):  
Chinmay Jani ◽  
Dominic C Marshall ◽  
Harpreet Singh ◽  
Joseph Shalhoub ◽  
Justin Salciccioli
Keyword(s):  
Lung Cancer ◽  
Cancer Mortality ◽  
Lung Cancer Mortality ◽  
World Health ◽  
Mortality Data ◽  
Male Mortality ◽  
Standard Population ◽  
The World ◽  
Males And Females ◽  
The Eu

e19277 Background: The lung is the commonest site of cancer and has the highest worldwide cancer-related mortality. Past two decades has seen advancements in screening technologies and guidelines, as well as new modalities for treatment. Few studies have reported on lung cancer trends in the 21st century. Our study reports and compares trends in lung cancer mortality in the USA and European Union (EU). Methods: We utilized the World Health Organization (WHO) Mortality Database and Center for Disease Control (CDC) Wonder database. We extracted Lung Cancer mortality data from 2001 to 2017 based on ICD 10 system. Crude mortality rates were dichotomized by sex and reported by year. We computed Age Standardized Death Rates (ASDRs) per 100,000 population using the World Standard Population and USA Standard Population. Lung cancer mortality trends were compared using Joinpoint regression analysis. Results: We analyzed a data from a total of 26 EU countries and USA, of which 6 countries had data till 2017, 12 till 2016, 7 till 2015 and 2 till 2014. We observed that mortality in men was down-trending in all countries except Cyprus and Portugal. In females, there was an increase in mortality in 22 countries. Amongst EU nations, most recently (2017) Hungary had the highest ASDRs for both males and females (64.5/100,000 and 31.0/100,000), whereas the lowest mortality was in Sweden for males (17.3/100,000) and Lithuania for the females (7.58/100,000). Latvia had the highest Estimated Annual Percentage Change (EAPC) in male mortality (-9.6%). Based on recent most data, we saw that there was a significantly lower mortality in males amongst European nations that joined the EU pre-2004 as compared to those that joined the EU post-2004 (p = 0.006). In USA, ASDRs in males and females were 44.3/100,000 and 30.6/100,000, respectively, with EAPC of -5.1% and -4.2% in males and females, respectively. Conclusions: For the study period, we observed expected decrease in lung cancer mortality in males. In contrast, there was a gradual rising trend in lung cancer mortality amongst females. In addition, there was substantial variation between nations. USA has shown consistent downtrend since 2001 where as there have been fluctuations in trends in other EU nations.

ROS1-rearranged lung adenocarcinoma with peritoneal carcinomatosis on initial presentation

2020 ◽  
Vol 13 (3) ◽  
pp. e233864
Author(s):  
Vera Kazakova ◽  
Sylvia V Alarcon Velasco ◽  
Aleksandr Perepletchikov ◽  
Christopher S Lathan
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Peritoneal Carcinomatosis ◽  
Poor Prognosis ◽  
Primary Tumour ◽  
Small Cell ◽  
Small Cell Lung ◽  
Peritoneal Spread ◽  
New Onset

Peritoneal carcinomatosis (PC) is progression of the primary cancer to the peritoneum that is seen in only 1.2% of patients with lung cancer. It is associated with poor prognosis especially if present at the time of initial cancer diagnosis. The predisposing factors for peritoneal spread are not yet well understood. It has been suggested that the oncogene status of the tumour can influence the patterns of metastatic spread. There is not enough data about the role of c-ROS oncogene 1 (ROS1) mutation in the development of PC in non-small cell lung cancer. Here, we describe a case of a 56-year-old man who presented with new-onset ascites and was found to have PC. He was diagnosed with ROS1-rearranged lung adenocarcinoma. No obvious primary tumour was identified. Patient responded well to targeted therapy with crizotinib and remained 6 months free of disease progression.

LIFE SPAN PREDICTION AT METASTATIC NON-SMALL CELL LUNG CANCER

2018 ◽  
Vol 64 (4) ◽  
pp. 522-527
Author(s):  
Aleksey Shutko ◽  
Viktor Mus
Keyword(s):  
Lung Cancer ◽  
Stem Cells ◽  
Small Cell Lung Cancer ◽  
Life Span ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
Hemopoietic Stem Cells ◽  
Small Cell Lung ◽  
Individual Life

Individual parameters of circulating hemopoietic stem cells (HSC) lymphoid origin were measured by cytofluorometry before treatment of patients with metastatic non-small cell lung cancer and were retrospectively compared with individual life span's (LS). The possibility of poor prognosis of treatment's results (LS

Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers

2019 ◽  
Vol 19 (23) ◽  
pp. 2128-2142 ◽  
Author(s):  
Hao He ◽  
Chang Xu ◽  
Zhao Cheng ◽  
Xiaoying Qian ◽  
Lei Zheng
Keyword(s):  
Lung Cancer ◽  
Adjuvant Therapy ◽  
Combination Therapy ◽  
Clinical Benefit ◽  
Poor Prognosis ◽  
Egfr Mutations ◽  
Kras Mutations ◽  
Lung Cancers ◽  
Egfr Tki ◽  
Egfr Tkis

: KRAS is the most common oncogene to be mutated in lung cancer, and therapeutics directly targeting KRAS have proven to be challenging. The mutations of KRAS are associated with poor prognosis, and resistance to both adjuvant therapy and targeted EGFR TKI. EGFR TKIs provide significant clinical benefit for patients whose tumors bear EGFR mutations. However, tumors with KRAS mutations rarely respond to the EGFR TKI therapy. Thus, combination therapy is essential for the treatment of lung cancers with KRAS mutations. EGFR TKI combined with inhibitors of MAPKs, PI3K/mTOR, HDAC, Wee1, PARP, CDK and Hsp90, even miRNAs and immunotherapy, were reviewed. Although the effects of the combination vary, the combined therapeutics are one of the best options at present to treat KRAS mutant lung cancer.

Cancer as a Scottish Problem

1968 ◽  
Vol 13 (10) ◽  
pp. 338-348
Author(s):  
A. J. Haddow
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cause Of Death ◽  
Cancer Mortality ◽  
Time Lag ◽  
Age Distribution ◽  
Lung Cancer Mortality ◽  
Cervix Uteri ◽  
Hospital Treatment ◽  
Cancer Of The Lung

Cancer, responsible for about 1 death in 5 in Scotland, cost over £1 per head of population in 1965 and led to bed occupation of almost 2,000 bed years. Time lag (symptoms-doctor-hospital-treatment) is usuallv small. Age distribution is as in other European countries. Excluding accidents, cancer is the second most important cause of death in children. In relation to other countries Scotland's position is very poor and the lung cancer mortality in both sexes is the highest known. Lung cancer is the most important in males, breast cancer in females. Alimentary cancers come second in both sexes. In this century alimentary cancers increased till the thirties or forties and then declined. Cancers of pancreas, cervix uteri, ovary, prostate, kidney and bladder, together with leukaemia, have all increased. Cancer of the lung has increased elevenfold in women and fiftyfold in men. It now accounts for 9 to 12 per cent of all male deaths in cities and large towns

Sign in / Sign up

Export Citation Format

Share Document